NO20062098L - Faststofftilstandmontelukast - Google Patents

Faststofftilstandmontelukast

Info

Publication number
NO20062098L
NO20062098L NO20062098A NO20062098A NO20062098L NO 20062098 L NO20062098 L NO 20062098L NO 20062098 A NO20062098 A NO 20062098A NO 20062098 A NO20062098 A NO 20062098A NO 20062098 L NO20062098 L NO 20062098L
Authority
NO
Norway
Prior art keywords
compound
formula
faststofftilstandmontelukast
formulated
precipitation
Prior art date
Application number
NO20062098A
Other languages
English (en)
Inventor
Dennie Johan Marijn Van Heuvel
Arjanne Overeem
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34520017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062098(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20062098L publication Critical patent/NO20062098L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En faststofform av en forbindelse av formel (1) er tilveiebrakt. Forbindelsen av formel (1) kan oppnås i faststofftilstand ved utfelling fra en løsning som inneholder det samme. Forbindelsen er nyttig som leukotrien antagonist og kan formuleres til en farmasøytisk sammensetning som også inkluderer en farmasøytisk akseptabel eksipient.
NO20062098A 2003-10-10 2006-05-10 Faststofftilstandmontelukast NO20062098L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50995703P 2003-10-10 2003-10-10
PCT/EP2004/011430 WO2005040123A1 (en) 2003-10-10 2004-10-08 Solid-state montelukast

Publications (1)

Publication Number Publication Date
NO20062098L true NO20062098L (no) 2006-05-10

Family

ID=34520017

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062098A NO20062098L (no) 2003-10-10 2006-05-10 Faststofftilstandmontelukast

Country Status (12)

Country Link
US (1) US7553853B2 (no)
EP (1) EP1678139B1 (no)
JP (2) JP2007508271A (no)
AT (1) ATE522507T1 (no)
AU (1) AU2004283832B2 (no)
CA (1) CA2541994A1 (no)
ES (1) ES2371549T3 (no)
IL (1) IL174758A (no)
NO (1) NO20062098L (no)
PT (1) PT1678139E (no)
WO (1) WO2005040123A1 (no)
ZA (1) ZA200602837B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
IL174758A (en) 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
US20070225325A1 (en) * 2004-01-28 2007-09-27 Pliva-Istrazivanje I Razvoj D.O.O. Solid Forms of Montelukast Acid
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
WO2005075427A2 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
EP1760077A1 (en) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
JP2007520546A (ja) 2004-02-03 2007-07-26 ケマジス リミティド モンテルカストナトリウムの安定な非晶質性形態
JP2007532686A (ja) 2004-04-21 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムを調製する方法
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
ATE500225T1 (de) * 2004-07-19 2011-03-15 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen davon
US9149472B2 (en) * 2004-08-31 2015-10-06 Jack William Schultz Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
EP1817289A1 (en) * 2004-11-30 2007-08-15 Medichem, S.A. New process for the preparation of a leukotriene antagonist
WO2006064269A2 (en) * 2004-12-17 2006-06-22 Cipla Limited Salts of leukotriene antagonist montelukast
CN101213177A (zh) * 2005-07-05 2008-07-02 特瓦制药工业有限公司 孟鲁司特的纯化
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
EP1968943B1 (en) * 2005-12-13 2013-01-23 MSN Laboratories Limited An improved process for the preparation of montelukast and its pharmaceutically acceptable salts
EP1803457A1 (en) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition containing montelukast
SI1976522T2 (sl) * 2005-12-30 2019-11-29 Krka Tovarna Zdravil D D Novo Mesto Farmacevtski sestavek, ki vsebuje montelukast
SI1818057T1 (sl) * 2006-02-09 2010-08-31 Teva Pharma Stabilne farmacevtske formulacije montelukast natrija
CN101432267A (zh) * 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
EP1886998A1 (en) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Purification process of montelukast and its amine salts
SI22382A (sl) * 2006-10-26 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek za pripravo montelukasta
WO2008062478A2 (en) * 2006-11-20 2008-05-29 Manne Satyanarayana Reddy Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
WO2009052624A1 (en) * 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Combination therapy
WO2009098271A1 (en) * 2008-02-06 2009-08-13 Farmaprojects, S.A. Process for the purification of montelukast by the preparation of acid addition salts and tert-amylamine salt
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
US8658208B2 (en) 2010-02-26 2014-02-25 Toray Industries, Inc. Coated solid preparation
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
CN106456535B (zh) 2014-04-25 2020-07-03 R.P.谢勒技术有限公司 稳定的孟鲁司特溶液
KR20210042412A (ko) 2018-09-06 2021-04-19 주식회사 이노파마스크린 천식 또는 파킨슨병 치료를 위한 방법 및 조성물
CN111307979A (zh) * 2020-03-14 2020-06-19 鲁南制药集团股份有限公司 一种孟鲁司特钠及其制剂的有关物质检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266568A (en) 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
ES2114882T3 (es) 1990-10-12 1998-06-16 Merck Frosst Canada Inc Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.
US5428033A (en) * 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW416948B (en) 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
BR0114792A (pt) * 2000-10-20 2003-08-12 Lilly Co Eli Composto cristalino, anidro, não solvatado, de cloridreto de 6-hidróxi-3-(-4-[2-piperidin-1-il)-etóxi]-fenóxi)-2-(4-metóx i-fenil)-benzol[b]tiofeno (f-v), formulação farmacêutica, processo para preparar um composto, e uso de um composto
CN1420113A (zh) * 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) * 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
WO2003066598A1 (en) * 2002-02-07 2003-08-14 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
PT1631550E (pt) * 2003-06-06 2012-04-19 Morepen Lab Ltd Um método melhorado para a preparação do ácido montelucaste e do seu sal de sódio na forma amorfa
IL174758A (en) 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
WO2005074935A1 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7189853B2 (en) 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor

Also Published As

Publication number Publication date
US20050107426A1 (en) 2005-05-19
IL174758A0 (en) 2006-08-20
JP2012072149A (ja) 2012-04-12
IL174758A (en) 2012-09-24
US7553853B2 (en) 2009-06-30
WO2005040123A1 (en) 2005-05-06
EP1678139A1 (en) 2006-07-12
AU2004283832B2 (en) 2011-04-07
JP2007508271A (ja) 2007-04-05
ES2371549T3 (es) 2012-01-05
CA2541994A1 (en) 2005-05-06
ATE522507T1 (de) 2011-09-15
AU2004283832A1 (en) 2005-05-06
EP1678139B1 (en) 2011-08-31
PT1678139E (pt) 2011-11-28
ZA200602837B (en) 2007-09-26

Similar Documents

Publication Publication Date Title
NO20062098L (no) Faststofftilstandmontelukast
TW200608972A (en) Aryl-pyridine derivatives
TW200616976A (en) Pyrimidine derivatives
LUC00155I2 (no)
TW200738241A (en) Pyridazine derivatives
TW200626558A (en) Indazolone derivatives
TW200740764A (en) Pyrazolone derivatives
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
ATE349432T1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
MX2010005824A (es) Derivados de aminotiazol.
RS20050469A (en) Pyrrolopyrimidine derivatives
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
GEP20094676B (en) Piperidine compounds and pharmaceutical compositions containing them
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
IS7482A (is) Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf
MX2009003169A (es) Derivados de sulfonamida.
BRPI0514415A (pt) composto, composição farmacêutica, e, uso de um composto
MY135646A (en) Indolyl derivatives
HRP20060023A2 (en) Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
ATE308540T1 (de) Antithrombosemittel
GB0212410D0 (en) Organic compounds
DE60222131D1 (de) Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application